Capital increase of 35 percent: Bayer implements glyphosate phase-out – share price rises!
Bayer CEO Anderson is considering a US exit from glyphosate. Lawsuits are putting the company under massive pressure. A capital increase is expected to help turn things around – the stock is reacting positively.
Summarized for you
The chemical and pharmaceutical company Bayer is openly questioning the continued existence of its glyphosate business in the United States. CEO Bill Anderson stated in a speech released in advance of the annual general meeting on April 25 that the company is approaching a critical point: "We are even slowly approaching a point where the litigation industry could force us to stop marketing this system-critical product."
This statement fuels speculation in the markets about a possible sale of the US business with the controversial weed killer Roundup, once part of the Monsanto takeover.
Short
Long
wallstreetONLINE Editorial Team
0 followersShow more
Show more
Written by 
Gina Moesing
wallstreet-online
